Can This Beaten-Down Marijuana Stock Roar Back in 2018?

There was good news and bad news for Zynerba Pharmaceuticals (NASDAQ: ZYNE) in 2017. First, the good news: The cannabinoid-focused biotech stock is up more than 90% over the last three months. What's the bad news? That gain wasn't enough to offset Zynerba's previous decline. The stock is still down over 20% year to date.

Will Zynerba's fortunes in 2018 be more like the first nine months of this year, or the last part of the year? Whether or not the marijuana stock's rebound continues hinges on what happens with cannabidiol (CBD) gel ZYN002 on several fronts.

Image source: Getty Images.

Source: Fool.com